Since the 1970s, excessive dopaminergic PROCEEDINGS
|
|
- Albert Allison
- 6 years ago
- Views:
Transcription
1 BIOLOGIC MECHANISMS OF PSYCHOSIS AND ANTIPSYCHOTIC DRUG ACTIONS: FROM DOPAMINE EXCESS TO DOPAMINE STABILIZATION * Bryan L. Roth, MD, PhD ABSTRACT *Based on a presentation given by Dr Roth at a symposium held in conjunction with the 2003 American Psychiatric Association Annual Meeting. Professor, Department of Biochemistry, Case Western Reserve University School of Medicine, Cleveland, Ohio. Address correspondence to: Bryan L. Roth, MD, PhD, Room W438, Department of Biochemistry, Case Western Reserve University, Euclid Avenue, Cleveland, OH roth@biochemistry.cwru.edu. According to the dopamine hypothesis of schizophrenia, symptoms of psychosis arise, in part, from dysregulation of central dopaminergic pathways. The activity of dopaminergic neurons is in turn modulated by several neurotransmitters, including, most prominently, serotonin and glutamate. The first generation of antipsychotic drugs (ie, typical antipsychotics) are characterized by potent D 2 dopamine receptor blockade, whereas most second-generation (ie, atypical) antipsychotics are serotonin-dopamine receptor antagonists. By simultaneously blocking both 5-HT 2A serotonin and D 2 dopamine receptors, atypical antipsychotic drugs attenuate the positive symptoms of schizophrenia with few of the extrapyramidal side effects associated with typical antipsychotic drugs. Unfortunately, atypical antipsychotic drugs (eg, clozapine, olanzapine, risperidone, quetiapine, and ziprasidone) can be associated with potentially serious side effects (eg, weight gain, cardiovascular and hematologic abnormalities). Conventional atypical antipsychotic drugs interact with a multiplicity of receptors, in addition to 5-HT 2A serotonin and D 2 dopamine receptors, including various serotonergic, dopaminergic, noradrenergic, muscarinic, and histaminergic receptors. It is likely that the chance interactions of atypical antipsychotic drugs with these and other receptors lead to the associated side effects. The ideal antipsychotic would, therefore, possess a mechanism of action whereby dopaminergic activity is normalized without adverse effects. (Adv Stud Med. 2003;3(8C):S776-S781) Since the 1970s, excessive dopaminergic activity has been the most prominent pharmacologic model for explaining the pathogenesis of schizophrenia, in large part because all effective antipsychotic drugs inhibit dopaminergic neurotransmission. 1 A number of dopaminergic pathways have been implicated in antipsychotic drug actions (Table 1). 2 Thus, positive symptoms of psychosis are believed to arise from excess dopaminergic activity in the mesolimbic pathway, whereas negative and cognitive symptoms are believed to arise from a deficiency in dopaminergic signaling in the mesocortical pathway. 3,4 First-generation antipsychotic agents suppress positive symptoms through their potent antagonism of D 2 dopamine receptors in the mesolimbic and mesocortical pathways. However, this mechanism of action may further diminish cognition via suppression of dopamine activity in the cortex. 5 Blockade of dopamine activity in the nigrostriatal pathway acutely causes extrapyramidal symptoms (eg, Parkinsonism, acute dystonias) and, chronically, tardive dyskinesia. Suppression of dopaminergic neurotransmis- S776 Vol. 3 (8C) September 2003
2 sion in the tuberoinfundibular pathway disinhibits prolactin secretion, leading to hyperprolactinemia and subsequent effects on fertility and sexual function. In addition to blockade of D 2 dopamine receptors, many atypical antipsychotic drugs have potent antimuscarinic, antialpha 1 -adrenergic, and/or antihistaminergic actions that produce additional side effects, including cognitive blunting, orthostatic hypotension, and sedation. An abundance of evidence suggests that a dysfunction of serotonin (5-hydroxytryptamine [5-HT]) neurotransmitter systems also contributes to the pathogenesis of schizophrenia and related psychoses HT is an indolamine neurotransmitter found in both the central nervous system and in the periphery, where it contributes to a number of physiological functions (eg, cognition, perception, memory, emotion, platelet aggregation, smooth muscle contraction). 8 It has long been recognized that blockade of the 5-HT 2A serotonin receptor subtype is an important part of atypical antipsychotic drug action, 11,12 and recent research is helping us to better understand why. We now know that 5-HT 2A receptors are highly enriched on the pyramidal neurons in the cortex. 13,14 These neurons integrate cognitive, emotional, and perceptual input to the brain prior to outputting the information to higherlevel neurons to create an individual s sense of reality. 5-HT 2A receptors are highly localized to a particular part of the pyramidal neuron that serves as the physical gate for information transfer in the brain (Figure 1). 15,16 Thus, it is now believed that blockade of the 5-HT 2A receptor normalizes the firing of pyramidal neurons, thereby stabilizing perception of reality. This assumption is based on a convergence of evidence relating to the action of a variety of drugs. Thus, hallucinogens, such as lysergic acid diethylamide (LSD) activate 5-HT 2A receptors, whereas all approved atypical antipsychotic drugs are potent 5-HT 2A receptor antagonists. It is believed that long-term treatment with atypical antipsychotic drugs normalizes the receptor-mediated signaling in cortical pyramidal neurons, thereby improv- Table 1. Dopamine Tracks and Effects of Antipsychotics Antipsychotic Dopamine Track Origin Innervation Function Effect Mesolimbic Midbrain Limbic Emotional Hallucinations, ventral structure and and delusions, tegmental nucleus intellectual disordered accumbens cognition Mesocortical Ventral Frontal Emotional Delusions, tegmental cortex and hallucinations, intellectual negative symptoms, disordered cognition Nigrostriatal Substantia Basal Extrapyramidal Motor nigra ganglia system symptomatology movement Tuberoinfundibular Hypothalamus Pituitary Regulates Plasma gland endocrine prolactin functions levels Adapted from DiPiro et al, eds. Pharmacotherapy: A Pathophysiologic Approach. New York: McGraw Hill/Appleton & Lange; Adapted with permission from the McGraw-Hill Companies. Figure 1. 5-HT 2A Serotonin Receptor I II III IV V VI Cerebral Cortex Cortical Surface White Matter Pyramidal Neuron Apical Dendrite Basal Dendrites Cell Body Inputs typically are scattered over the neuron s dendritic tree Branching axon is the neuron s output (the junction is the synapse) Adapted with permission from Calvin et al. Conversations with Neil s Brain: The Neural Nature of Thought and Language. Oxford, UK: Perseus Publishing; Advanced Studies in Medicine S777
3 ing positive and negative symptoms of schizophrenia. When activated, 5-HT 1A serotonin receptors, co-localized on pyramidal neurons with 5-HT 2A receptors, also inhibit the firing of pyramidal neurons. Thus, in theory, an ideal drug for normalizing the firing of pyramidal neurons would both activate 5-HT 1A receptors and antagonize 5-HT 2A receptors. Because pyramidal neurons are glutamatergic, activating 5-HT 1A receptors and inhibiting 5-HT 2A receptors may stabilize glutamatergic neurotransmission. Finally, 5-HT 1A partial agonists stabilize the serotonergic system because they are serotonin autoreceptors. Three approved atypical antipsychotic drugs have these opposing actions on 5-HT 1A and 5-HT 2A serotonin receptors: aripiprazole, clozapine, and ziprasidone. Thus, therapy with aripiprazole, clozapine, or ziprasidone is predicted to be associated with a stabilization of the serotonergic and glutamatergic neurotransmission. The pharmacology of these drugs, and atypical drugs in general, is highly complex, however they interact with numerous other receptors, 17 and interactions with other receptors may modulate the actions of antipsychotic drugs on a number of neurotransmitter systems. RESOURCE FOR IDENTIFYING MOLECULAR TARGETS Determining which pharmacologic actions are essential to achieve therapeutic effects and which generate side effects has become increasingly difficult. The National Institute of Mental Health Psychoactive Drug Screening Program (NIMH-PDSP) has created a unique resource in the public domain that provides information on the abilities of drugs to interact with an expanding number of molecular targets. The NIMH-PDSP database serves as a data warehouse for published and internally derived K i, or affinity, values for a large number of drugs and drug candidates at an expanding number of G-protein coupled receptors, ion channels, transporters, and enzymes. The flexible user interface provides for customized data mining. Planned enhancements include: (1) a searchable database of agonist/antagonist properties of drugs and drug candidates at various molecular targets; and (2) a chemi-informatics interface, which will allow the user to search the database by homology. The query interface is designed to allow search by any field, or a combination of fields to refine search criteria. Both antipsychotics and drugs of abuse are listed in the database, which provides a listing of the various receptors with which the drug has an affinity (including those identified by the human genome project), the chemical structure of the drugs, and a link to the published material. The NIMH-PDSP database is a unique resource in the public domain that provides information on the abilities of drugs to interact with an expanding number of molecular targets. For clinicians, this resource provides a valuable tool for predicting both therapeutic efficacy and side effects of individual medications. It is available at Using the NIMH-PDSP database, an analysis of molecular targets for clozapine shows that it is likely to occupy not only the D 2 dopamine and 5-HT 2A receptors, but also a large number of other receptors. The analysis of molecular targets also suggests that even at the highest doses of clozapine clinically achievable, dopamine D 2 receptor occupancy will not exceed 70%, and will typically be less. Studies of in vivo receptor occupancy with positron emission tomography scanning have supported such molecular predictions. 18 At the opposite end of the spectrum is aripiprazole, whose structure and in vitro pharmacology is markedly dissimilar from clozapine. Analysis of molecular targets for this drug shows that at the usual clinical dose, it is predicted to occupy more than 90% of dopamine D 2 and D 3 receptors, as well as 5-HT 1A receptors. Clinical studies of aripiprazole show that a dose of 30 mg daily achieved nearly 100% occupancy of striatal D 2 dopamine receptors in normal human volunteers. 19 Although classic pharmacologic theory would indicate that complete occupancy of D 2 receptors will result in significant side effects, clinically, aripiprazole has been found to be nearly devoid of extrapyramidal side effects and does not trigger the elevation of serum prolactin that is reported with use of typical antipsychotic drugs. 20 This seeming contradiction can be explained by a closer analysis of aripiprazole s pharmacology. Because aripiprazole is a partial agonist, when it binds to the D 2 receptor it partially activates the D 2 dopamine receptor, thus resetting the functional activity of the D 2 receptor to a lower level. In this way, partial agonists are unlike antagonists, which set the functional state of occupied D 2 S778 Vol. 3 (8C) September 2003
4 receptors to zero. Thus, in a situation in which excessive dopamine is released (eg, the acute psychotic state) and D 2 dopamine receptors are fully activated, a partial agonist will reset the receptor tone to a more normal level. In conditions in which too little dopamine is released (eg, in the prefrontal cortex of schizophrenic individuals) one would predict that a partial agonist would yield a net activation of D 2 dopamine receptors. The level of agonist activity seen with partial agonists like aripiprazole is thought to be sufficient to functionally reset the dopaminergic system to achieve the 70% occupancy level seen with clozapine, thereby yielding the same net effect on dopaminergic neurotransmission. A simulation performed by the NIMH-PDSP of aripiprazole s partial agonist activity on dopamine and serotonergic receptor occupancy demonstrates the predicted functional effect (B.L. Roth, manuscript in preparation). years and remains a serious side effect of some antipsychotic drugs. 23,24 The mechanism responsible for antipsychotic drug induced weight gain is somewhat controversial, though clinicians have reported tremendous increases in appetite in schizophrenic patients Table 2. Receptor Pharmacology Reliably Predicts Side Effects* Associated Receptor Side Effect Ari Olz Ris Zip Clz Hal Alpha 1A Hypotension, dizziness H 1 Sedation M 1 Blurred vision, dry mouth SIDE EFFECTS AND WEIGHT GAIN A detailed knowledge of receptor pharmacology can also be used to predict the side-effect profiles of individual drugs. By identifying the type and number of receptors occupied, we can reliably predict the likelihood of specific side effects. For example, analysis of clozapine with the NIMH-PDSP database demonstrates extensive interactions with a host of receptors that are responsible for many of the drug s side effects. For example, alpha 1 -adrenergic receptor blockade results in hypotension, and muscarinic receptor blockade results in anticholinergic side effects. A similar analysis of haloperidol s receptor interactions predicts few alpha 1 -adrenergic receptor side effects, little interaction with the H 1 receptor (eg, minimal sedation and weight gain), and little interaction with muscarinic receptors, leading to few anticholinergic side effects. Simulations with aripiprazole also demonstrate little activity with these receptors, predictive of few side effects (Table 2) 17,21,22 ; clinical trials indicate that aripiprazole is associated with few adrenergic, histaminergic, or cholinergic side effects. 20 Weight gain as a side effect of antipsychotic therapy has been noted for more than 30 = no effect; + = minimal side effects; ++ = moderate side effects; +++ = strong side effects. *All data obtained with cloned human receptors. Ari = aripiprazole; Olz = olanzapine; Ris = risperidone; Zip = ziprasidone; Clz = clozapine; Hal = haloperidol. Data from Shapiro et al 21 ; Kroeze et al 22 ; Roth et al. 17 Figure 2. Mean Weight Change at 10 Weeks in Patients Taking Antipsychotics at Standard Dose *4-6 week pooled data from Marder et al. 27 Extrapolated from 6-week data. Adapted with permission from Allison et al. Am J Psychiatry. 1999;156: Copyright 1999, the American Psychiatric Association; Advanced Studies in Medicine S779
5 leading to substantial weight gain, 25 with significant implications for metabolic side effects, such as diabetes and hyperlipidemia. 26 To assess correlations between specific antipsychotic drug agents and weight gain, Allison et al conducted a retrospective study that showed a strong association with clozapine and olanzapine use. 25 Figure 2 extrapolates data from Allison s 1999 analysis and pools it with later data from a multicenter trial assessing weight in patients using aripiprazole. 25,27 The mechanism responsible for antipsychotic drug induced weight gain is unknown, although recent studies have suggested an association between weight gain and a silent polymorphism of the 5-HT 2C receptor. 28 Although many antipsychotic drugs interact with 5-HT 2C receptors, 29 the propensity of antipsychotic drugs to induce weight gain does not correlate with their actions at 5-HT 2C receptors, indicating that some other receptor(s) are likely responsible for this serious side effect. Kroeze et al recently reported results based on a test of the hypothesis that the affinity of an antipsychotic for a certain receptor or subset of receptors will predict whether it induces weight gain, and that this group of receptors would differ from those that predict effectiveness. 22 The investigators obtained weight-gain data for antipsychotic drugs from the meta-analysis published by Allison et al 25 and from the multicenter aripiprazole study 27 and utilized receptor affinity data from the NIMH-PDSP to identify correlations between weight gain and receptor affinities. They found 2 receptors that were responsible for predicting with the highest degree of certainty whether a drug will or will not induce weight gain: the H 1 histamine receptor and the alpha 1 -adrenergic receptor. An individual drug s ability to interact with these 2 receptors was highly predictive of its ability to induce weight gain. The binding data from Kroeze s analysis suggests that 2 atypical antipsychotic drugs will not induce substantial weight gain over a 10-week period: ziprasidone and aripiprazole. Clinical trial data also report that aripiprazole and ziprasidone have a relatively low propensity to induce weight gain. CONCLUSION Multiple receptors are occupied by antipsychotic drugs, which may activate or inhibit receptor activity. Drugs with dopamine partial/functional agonism may stabilize the dopaminergic system with minimal extrapyramidal symptoms. Antagonism of the 5-HT 2A receptor stabilizes a number of neurotransmitter systems, likely accounting for the salutary effects of atypical antipsychotic medications on cognition and mood. Drugs with 5-HT 1A receptor agonism further stabilize various neurotransmitter systems (glutamatergic and serotonergic); this action may account for the mood stabilization seen in patients taking certain atypical antipsychotic drugs. Potent H 1 -receptor antagonism is associated with weight gain and sedation, and drugs with minimal H 1 -receptor antagonism are relatively devoid of these side effects. A detailed knowledge of receptor pharmacology allows reliable prediction of benefits and side effects of antipsychotic drugs. REFERENCES 1. Goff DC, Heckers S, Freudenreich O. Schizophrenia. Med Clin North Am. 2001;85: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: A Pathophysiologic Approach. 5th ed. New York: McGraw Hill/Appleton & Lange; Egan MF, Goldberg TE, Kolachana BS, et al. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci U S A. 2001;98: Abi-Dargham A, Mawlawi O, Lombardo I, et al. Prefrontal dopamine D1 receptors and working memory in schizophrenia. J Neurosci. 2002;22: Castner SA, Williams GV, Goldman-Rakic PS. Reversal of antipsychotic-induced working memory deficits by short-term dopamine D1 receptor stimulation. Science. 2000;287: Kroeze WK, Roth BL. The molecular biology of serotonin receptors: therapeutic implications for the interface of mood and psychosis. Biol Psychiatry. 1998;44: Kahn R, Davidson M. Serotonin, dopamine and their interactions in schizophrenia. Psychopharmacology (Berl). 1993;112(1 suppl):s1-s4. 8. Roth BL, Berry SA, Kroeze WK, Willins DL, Kristiansen K. Serotonin 5-HT2A receptors: molecular biology and mechanisms of regulation. Crit Rev Neurobiol. 1998;12: Meltzer HY. The role of serotonin in antipsychotic drug action. Neuropsychopharmacology. 1999;21:106S-115S. 10. Roth B, Meltzer H. The role of serotonin in schizophrenia. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. 4th ed. New York: Raven Press; 1995: Meltzer HY, Matsubara S, Lee JC. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin-2 pki values. J Pharmacol Exp Ther. 1989;251: Rasmussen K, Aghajanian GK. Potency of antipsychotics in reversing the effects of a hallucinogenic drug on locus S780 Vol. 3 (8C) September 2003
6 coeruleus neurons correlates with 5-HT2 binding affinity. Neuropsychopharmacology. 1988;1: Willins DL, Deutch AY, Roth BL. Serotonin 5-HT2A receptors are expressed on pyramidal cells and interneurons in the rat cortex. Synapse. 1997;27: Jakab RL, Goldman-Rakic PS. 5-hydroxytryptamine-2A serotonin receptors in the primate cerebral cortex: possible site of action of hallucinogenic and antipsychotic drugs in pyramidal cell apical dendrites. Proc Natl Acad Sci U S A. 1998;95: Willins DL, Berry SA, Alsayegh L, et al. Clozapine and other 5-hydroxytryptamine-2A receptor antagonists alter the subcellular distribution of 5-hydroxytryptamine-2A receptors in vitro and in vivo. Neuroscience. 1999;91: Calvin WH, Ojemann GA. Conversations with Neil s Brain: The Neural Nature of Thought and Language. Oxford, UK: Perseus Publishing; Roth B, Sheffler D, Potkin S. Atypical antipsychotic drugs: unitary or multiple mechanisms of atypicality. J Clin Neurosci. In press. 18. Trichard C, Paillere-Martinot M, Attar-Levy D, et al. Binding of antipsychotic drugs to cortical 5-HT2A receptors: a PET study of chlorpromazine, clozapine, and amisulpride in schizophrenic patients. Am J Psychiatry. 1998;155: Yokoi F, Grunder G, Biziere K, et al. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11c]raclopride. Neuropsychopharmacology. 2002;27: Kane JM, Carson WH, Saha AR, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry. 2002;63: Shapiro DA, Renock S, Arrington E, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology. 2003; 28(8): Kroeze WK, Hufeisen SJ, Popadak BA, et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology. 2003;28: Rockwell W, Ellinwood E, Trader D. Psychotropic drugs promoting weight gain: health risks and treatment implications. South Med J. 1983;76: Editorial: drugs causing weight gain. Br Med J. 1974; 1: Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156: Kurzthaler I, Fleischhacker WW. The clinical implications of weight gain in schizophrenia. J Clin Psychiatry. 2001; 62(suppl 7): Marder SR, McQuade RD, Stock E, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res. 2003; 61: Reynolds G, Zhang Z, Zhang X. Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism. Lancet. 2002;359: Rauser L, Savage J, Meltzer H, Roth B. Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine(2c) receptor. J Pharmacol Exp Ther. 2001;299: Advanced Studies in Medicine S781
Switching antipsychotics: Basing practice on pharmacology & pharmacokinetics
Switching antipsychotics: Basing practice on pharmacology & pharmacokinetics John Donoghue Liverpool L imagination est plus important que le savoir Albert Einstein Switching Antipsychotics: Objectives
More informationSP.236 / ESG.SP236 Exploring Pharmacology Spring 2009
MIT OpenCourseWare http://ocw.mit.edu SP.236 / ESG.SP236 Exploring Pharmacology Spring 2009 For information about citing these materials or our Terms of Use, visit: http://ocw.mit.edu/terms. Atypical (2
More informationESSENTIAL PSYCHOPHARMACOLOGY, Neurobiology of Schizophrenia Carl Salzman MD Montreal
ESSENTIAL PSYCHOPHARMACOLOGY, 2011 Neurobiology of Schizophrenia Carl Salzman MD Montreal EVOLVING CONCEPTS OF SCHIZOPHRENIA Psychotic illness with delusions, hallucinations, thought disorder and deterioration;
More informationChapter Chapter Chapter Chapter Chapter Chapter Chapter Chapter 8 Chapter
CONTENTS Preface Chapter 1 Principles of Chemical Neurotransmission Chapter 2 Receptors and Enzymes as the Targets of Drug Action Chapter 3 Special Properties of Receptors Chapter 4 Chemical Neurotransmission
More informationSchizophrenia. Psychology 372 Physiological Psychology. Overview. Characterized by. Disorganized Thoughts Hallucinations Delusions Bizarre behaviors
Overview Schizophrenia Psychology 372 Physiological Psychology Steven E. Meier, Ph.D. Listen to the audio lecture while viewing these slides Probably consists of more than one disorder Is the most devastating
More informationObjectives. Epidemiology. Diagnosis 3/27/2013. Identify positive and negative symptoms used for diagnosis of schizophrenia
Objectives Identify positive and negative symptoms used for diagnosis of schizophrenia Mohamed Sallout, Pharm D. Pharmacist Resident St. Luke s Magic Valley Regional Medical Center List medications used
More informationTreatments for Schizophrenia
Early treatments Treatments for Schizophrenia Psychology 311 Abnormal Psychology Trephining Open a hole in the skull Let out the evil spirit Some people even survived, had multiple holes with different
More informationDrugs for psychosis and mood: unique actions at D3, D2, and D1 dopamine receptor subtypes
CNS Spectrums (2017), 22, 375 384. Cambridge University Press 2017 doi:10.1017/s1092852917000608 Drugs for psychosis and mood: unique actions at,, and dopamine receptor subtypes Stephen M. Stahl ISSUE:
More informationSchizophrenia Pharmacology UNIVERSITY OF HAWAI I HILO PRE -NURSING PROGRAM
Schizophrenia Pharmacology UNIVERSITY OF HAWAI I HILO PRE -NURSING PROGRAM NURS 203 GENERAL PHARMACOLOGY DANITA NARCISO PHARM D Learning Objectives Understand the result of dopamine binding to D2 receptors
More informationPotential control of antipsychotic-induced hyperprolactinemia and obesity in children and adolescents by aripiprazole
University of Wollongong Research Online Faculty of Science, Medicine and Health - Papers Faculty of Science, Medicine and Health 2010 Potential control of antipsychotic-induced hyperprolactinemia and
More informationThe antipsychotic drugs (also called neuroleptics or major tranquilizers) are used primarily to treat schizophrenia, but they are also effective in
Antipsychotic Drugs The antipsychotic drugs (also called neuroleptics or major tranquilizers) are used primarily to treat schizophrenia, but they are also effective in other psychotic and manic states.
More informationCHAPTER 3. Schizophrenia and Antipsychotic Treatment
CHAPTER 3 Schizophrenia and Antipsychotic Treatment What is it? It is a severe, chronic, disabling brain disease Considered to have biological origins but exact unknown 1% of population affected Schizophrenia
More informationSchizophrenia: Uncovering a molecular origin so humanity may better deal with insanity
Schizophrenia: Uncovering a molecular origin so humanity may better deal with insanity : What is Schizophrenia? Literally split mind A mental disorder comprising most major psychotic disorders; characterized
More informationWESTMEAD PRIMARY EXAM GROUP PSYCHOTROPIC MEDICATIONS
WESTMEAD PRIMARY EXAM GROUP PSYCHOTROPIC MEDICATIONS DOPAMINE HYPOTHESIS Excessive limbic dopamine is hypothesised to cause psychosis Many antipsychotics inhibit dopamine 2 receptors in mesolimbic and
More informationANTIPSYCHOTIC POLYPHARMACY
Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences ANTIPSYCHOTIC POLYPHARMACY RYAN KIMMEL, MD MEDICAL DIRECTOR HOSPITAL PSYCHIATRY UWMC GENERAL DISCLOSURES The University
More informationSAFETY AND TOLERABILITY: HOW DO NEWER GENERATION ATYPICAL ANTIPSYCHOTICS COMPARE?
Psychiatric Quarterly, Vol. 73, No. 4, Winter 2002 ( C 2002) SAFETY AND TOLERABILITY: HOW DO NEWER GENERATION ATYPICAL ANTIPSYCHOTICS COMPARE? Rajiv Tandon, M.D. Previously, clinicians worked with antipsychotic
More informationSchizophrenic twin. Normal twin
Brain anatomy and activity are often abnormal in schizophrenics - many studies have found the ventricles in schizophrenic patients enlarged (see below). - at the structural level, several brain areas have
More informationAntipsychotics. Neuroleptics/ Major Tranquilizers. Hiwa K. Saaed, PhD Pharmacology & Toxicology /5/18 1
Antipsychotics Neuroleptics/ Major Tranquilizers Hiwa K. Saaed, PhD Pharmacology & Toxicology hiwa.saaed@univsul.edu.iq 2018-2019 12/5/18 1 Learning objectives Pharmacy students should: be familiar with
More informationCME Outfitters, LLC, is the accredited provider for this neurosciencecme continuing education activity.
CME Outfitters, LLC, is the accredited provider for this neurosciencecme continuing education activity. CME Outfitters, LLC, gratefully acknowledges an educational grant from Wyeth Pharmaceuticals and
More informationPharmacotherapy of psychosis and schizophrenia in youth
Pharmacotherapy of psychosis and schizophrenia in youth Benedetto Vitiello Pavia, 2 December 2017 Disclosure Benedetto Vitiello, M.D. Professor of Child and Adolescent Neuropsychiatry University of Turin,
More informationSchizophrenia. Psychotic Disorders. Schizophrenia. Chapter 13
Schizophrenia Chapter 13 Psychotic Disorders Symptoms Alternations in perceptions, thoughts, or consciousness (delusions and hallucination) DSM-IV categories Schizophrenia Schizophreniform disorder Schizoaffective
More informationPsychotic disorders are complex neurobiologic
XASIN_2_4_p135_145 10/25/04 3:40 PM Page 135 IMPROVING OUTCOMES FOR PATIENTS WITH PSYCHOTIC DISORDERS * Geoffry W. McEnany, RN, PhD, CS ABSTRACT In psychosis, appropriate prescribing and administration
More informationOut with the Old In with the New: Novel, Neuroscience-Based Re-Classification of Psychiatric Medications
Program Outline Out with the Old In with the New: Novel, Neuroscience-Based Re-Classification of Psychiatric Medications Rajiv Tandon, MD Professor of Psychiatry University of Florida College of Medicine
More informationWhat is the mechanism for aripiprazole's effect on reducing olanzapine-associated obesity?
University of Wollongong Research Online Faculty of Science, Medicine and Health - Papers Faculty of Science, Medicine and Health 2010 What is the mechanism for aripiprazole's effect on reducing olanzapine-associated
More informationRECEPTORS: RELEVANCE TO ANTIPSYCHOTIC DRUGS
Indian Journal of Pharmacology 2000; 32: 187-191 EDUCATIONAL FORUM AND 5HT 2 RECEPTORS: RELEVANCE TO ANTIPSYCHOTIC DRUGS Department of Pharmacology, Postgraduate Institute of Medical Education and Research,
More informationAntipsychotics. Something Old, Something New, Something Used to Treat the Blues
Antipsychotics Something Old, Something New, Something Used to Treat the Blues Objectives To provide an overview of the key differences between first and second generation agents To an overview the newer
More informationChapter 161 Antipsychotics
Chapter 161 Antipsychotics Episode Overview Extrapyramidal syndromes are a common complication of antipsychotic medications. First line treatment is benztropine or diphenhydramine. Lorazepam is used in
More informationDo we still believe in the dopamine hypothesis? New data bring new evidence
International Journal of Neuropsychopharmacology (24), 7 (Supplement 1), S1 S5. Copyright f 24 CINP DOI : 1.117/S146114574411 Do we still believe in the dopamine hypothesis? New data bring new evidence
More informationAntipsychotic Drugs. Munir Gharaibeh, MD, PhD, MHPE March, 2018
Antipsychotic Drugs Munir Gharaibeh, MD, PhD, MHPE March, 2018 المھدي ات( م ض ا د ا ت( Antipsychotic Drugs These are the drugs used in the treatment of psychotic diseases( e.g. schizophrenia). ا ل ك ب
More informationSchizophrenia & the Antipsychotics
splitting of mind (cognition/emotion) from reality 1% of population globally shamans or mentally ill Several subtypes: paranoid / catatonic / disorganized / undifferentiated / residual positive ( exaggerated)
More informationCogs 107b Systems Neuroscience lec9_ neuromodulators and drugs of abuse principle of the week: functional anatomy
Cogs 107b Systems Neuroscience www.dnitz.com lec9_02042010 neuromodulators and drugs of abuse principle of the week: functional anatomy Professor Nitz circa 1986 neurotransmitters: mediating information
More informationA Case of Hyper Sexuality Probably Associated with Clozapine
Complicated Case Histories Key Words: atypical antipsychotic, adverse drug reaction, hypersexuality A Case of Hyper Sexuality Probably Associated with Clozapine By Sereen Rose Thomson, Navin Patil, Balaji
More informationTreatment of Schizophrenia
Treatment of Schizophrenia Conduct comprehensive assessment and use measurement-based care as found in the Principles of Practice (review pages 4-7). Most importantly assess social support system (housing,
More informationPsychopharmacology. MATTHEW MACALUSO, DO ALEXANDRA FLYNN, MD, PhD SHELDON PRESKORN, MD
Psychopharmacology Determining Whether a Definitive Causal Relationship Exists Between Aripiprazole and Tardive Dyskinesia and/or Dystonia in Patients With Major Depressive Disorder, Part 2: Preclinical
More informationMOLECULAR BIOLOGY OF DRUG ADDICTION. Sylvane Desrivières, SGDP Centre
1 MOLECULAR BIOLOGY OF DRUG ADDICTION Sylvane Desrivières, SGDP Centre Reward 2 Humans, as well as other organisms engage in behaviours that are rewarding The pleasurable feelings provide positive reinforcement
More informationChemical Control of Behavior and Brain 1 of 9
Chemical Control of Behavior and Brain 1 of 9 I) INTRO A) Nervous system discussed so far 1) Specific 2) Fast B) Other systems extended in space and time 1) Nonspecific 2) Slow C) Three components that
More informationAntipsychotic treatment
Antipsychotic treatment Istvan Bitter 24 February 2010 Positive symptoms: delusions, hallucinations, disorganized thinking, excitement, agitation, aggressivity, other behavioral disturbances Negative symptoms:
More informationFinal Exam PSYC2022. Fall (1 point) True or False. The DSM-IV describes the symptoms of acute intoxication with cannabis.
Final Exam PSYC2022 Fall 1998 (2 points) Give 2 reasons why it is important for psychological disorders to be accurately diagnosed. (1 point) True or False. The DSM-IV describes the symptoms of acute intoxication
More informationAntipsychotic Medications
TRAIL: Team Review of EVIDENCE REVIEW & RECOMMENDATIONS FOR LTC Behavioural and psychological symptoms of dementia (BPSD) refer to the non-cognitive symptoms of disturbed perception, thought content, mood
More informationNeurotransmitters acting on G-protein coupled receptors
Neurotransmitters acting on G-protein coupled receptors Part 2: Serotonin and Histamine BIOGENIC AMINES Monoamines Diamine Indolamines: Serotonin Basic Neurochemistry. FIGURE 15-1: Chemical structure of
More informationWhat Have We Learned from Molecular Imaging Studies of Dopamine Neurotransmission in Schizophrenia and in Mediating Reward Behaviors
What Have We Learned from Molecular Imaging Studies of Dopamine Neurotransmission in Schizophrenia and in Mediating Reward Behaviors Robert M Kessler, MD Professor of Radiology University of Alabama at
More informationMethod. NeuRA Paliperidone August 2016
Introduction Second generation antipsychotics (sometimes referred to as atypical antipsychotics) are a newer class of antipsychotic medication than first generation typical antipsychotics. Second generation
More informationAnja Cerovecki Richard Musil Ansgar Klimke Florian Seemüller Ekkehard Haen Rebecca Schennach Kai-Uwe Kühn Hans-Peter Volz Michael Riedel
CNS Drugs (2013) 27:545 572 DOI 10.1007/s40263-013-0079-5 REVIEW ARTICLE Withdrawal Symptoms and Rebound Syndromes Associated with Switching and Discontinuing Atypical Antipsychotics: Theoretical Background
More informationNeurotransmitter Functioning In Major Depressive Disorder
Neurotransmitter Functioning In Major Depressive Disorder Otsuka Pharmaceutical Development & Commercialization, Inc. 2017 Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville, MD January
More informationNeurotransmitter Systems III Neurochemistry. Reading: BCP Chapter 6
Neurotransmitter Systems III Neurochemistry Reading: BCP Chapter 6 Neurotransmitter Systems Normal function of the human brain requires an orderly set of chemical reactions. Some of the most important
More informationNeurochemistry of psychiatric disorders. Dr. Radwan Banimustafa
Neurochemistry of psychiatric disorders Dr. Radwan Banimustafa Introduction Neurochemistry is the study of chemical interneuronal communication. Wilhelm and Santiago in the late 19 th century stated that
More information- Neurotransmitters Of The Brain -
- Neurotransmitters Of The Brain - INTRODUCTION Synapsis: a specialized connection between two neurons that permits the transmission of signals in a one-way fashion (presynaptic postsynaptic). Types of
More informationAntidepressants. Dr Malek Zihlif
Antidepressants The optimal use of antidepressant required a clear understanding of their mechanism of action, pharmacokinetics, potential drug interaction and the deferential diagnosis of psychiatric
More informationWith growing knowledge of disease
PHARMACOLOGIC STRATEGIES IN THE MANAGEMENT OF COGNITIVE SYMPTOMS Terry E. Goldberg, PhD* ABSTRACT Cognitive dysfunction is considered a major determinant and predictor of long-term disability and has,
More informationMaking Every Little Bit Count: Parkinson s Disease. SHP Neurobiology of Development and Disease
Making Every Little Bit Count: Parkinson s Disease SHP Neurobiology of Development and Disease Parkinson s Disease Initially described symptomatically by Dr. James Parkinson in 1817 in An Essay on the
More informationPsychobiology Handout
Nsg 85A / Psychiatric Page 1 of 7 Psychobiology Handout STRUCTURE AND FUNCTION OF THE BRAIN Psychiatric illness and the treatment of psychiatric illness alter brain functioning. Some examples of this are
More informationDiagnosis and treatment of acute agitation and aggression in patients with schizophrenia and bipolar disorder: evidence for the efficacy of atypical
Diagnosis and treatment of acute agitation and aggression in patients with schizophrenia and bipolar disorder: evidence for the efficacy of atypical antipsychotics 1 Abstract Acute agitation and aggression
More informationNew Medications in Early Psychosis
New Medications in Early Psychosis Jean Starling Department of Psychological Medicine, the Children s Hospital at Westmead Department of Psychological Medicine and Department of Paediatrics and Child Health,
More informationHearts and Minds An ECG Update. Tuesday 18 th November The Met Hotel, Leeds
Hearts and Minds An ECG Update Tuesday 18 th November The Met Hotel, Leeds Ashleigh Bradley Specialist Clinical Pharmacist for Mental Health and Lithium Clinic Airedale NHS Foundation Trust Introduction
More informationThe Nervous System. Chapter 4. Neuron 3/9/ Components of the Nervous System
Chapter 4 The Nervous System 1. Components of the Nervous System a. Nerve cells (neurons) Analyze and transmit information Over 100 billion neurons in system Four defined regions Cell body Dendrites Axon
More informationTest Bank for Essentials of Psychiatric Mental Health Nursing 1st Edition by Varcarolis
Test Bank for Essentials of Psychiatric Mental Health Nursing 1st Edition by Varcarolis Link download full: https://testbankservice.com/download/test-bankforessentials-of-psychiatric-mental-health-nursing-1st-editionbyvarcarolis/
More informationWhat's New in the World of Antipsychotics?
Handout for the Neuroscience Education Institute (NEI) online activity: What's New in the World of Antipsychotics? (page 7 in syllabus) Stephen M. Stahl, MD, PhD Adjunct Professor, Department of Psychiatry
More informationANTIPSYCHOTICS/ NEUROLEPTICS
Pharmacological Interventions Tutorial Antipsychotic medications First Generation (Typicals) Includes phenothiazines, thioxanthenes, butyrophenones ANTIPSYCHOTICS/ NEUROLEPTICS Second Generation (Atypicals)
More informationNeurophysiology and Neurochemistry in PsychoGeriatrics
Tel Aviv University Sackler Faculty of Medicine CME in Psychiatry Neurophysiology and Neurochemistry in PsychoGeriatrics Nicola Maggio, MD, PhD Sackler Faculty of Medicine Tel Aviv University Department
More informationNeurochemistry. Dr. Radwan Banimustafa
Neurochemistry Dr. Radwan Banimustafa Introduction Neurochemistry is the study of chemical inter-neuronal communication. Wilhelm and Santiago in the late 19 th century stated that the brain consists of
More informationbiological psychology, p. 40 The study of the nervous system, especially the brain. neuroscience, p. 40
biological psychology, p. 40 The specialized branch of psychology that studies the relationship between behavior and bodily processes and system; also called biopsychology or psychobiology. neuroscience,
More informationAcetylcholine (ACh) Action potential. Agonists. Drugs that enhance the actions of neurotransmitters.
Acetylcholine (ACh) The neurotransmitter responsible for motor control at the junction between nerves and muscles; also involved in mental processes such as learning, memory, sleeping, and dreaming. (See
More informationCariprazine is a newly approved
Cariprazine for schizophrenia and bipolar I disorder Gregory Mattingly, MD, and Richard Anderson, MD, PhD Cariprazine is a newly approved (September 2015) dopamine D3/D2 receptor partial agonist with higher
More informationRECEPTOR PROFILES OF THE ATYPICAL AGENTS
SCHIZOPHRENIA: FROM NEUROSCIENCE TO CLINICAL EXPERIENCE Peter F. Buckley, MD,* and Donald E. N. Addington, MBBS, MRCPsych, FRCPC ABSTRACT Typical first-generation agents work through potent blockade of
More informationOrganization of the nervous system. [See Fig. 48.1]
Nervous System [Note: This is the text version of this lecture file. To make the lecture notes downloadable over a slow connection (e.g. modem) the figures have been replaced with figure numbers as found
More informationSlide 1. Slide 2. Slide 3. Risperidone Binding Profile. Risperidone Prescribing Facts. Risperidone Prescribing Facts
Slide 1 Risperidone Binding Profile (high affinity for D2 receptors) a 1 antagonist a 2 antagonist Slide 2 Risperidone Prescribing Facts 2 8 mg/day for acute psychosis and bipolar disorder 0.5-2 mg /day
More informationLurasidone: A New Antipsychotic For Schizophrenia. Objectives. Introduction. Pharmacology/Pharmacokinetics. Mechanism of Action. Mechanism of Action
Lurasidone: A New Antipsychotic For Schizophrenia Theodore Pikoulas, PharmD PGY2 Psychiatric Pharmacy Resident Louis Stokes Cleveland VAMC Objectives Review the pharmacology and the pharmacokinetics Identify
More informationIt's a Brain Thing. Sue Gabriel Molly Gabriel
Tuesday, 10:00 11:30, A3 It's a Brain Thing Sue Gabriel 989-640-0628 scgabriel2@gmail.com Objectives: Molly Gabriel Notes: 1. Identify effective methods for the practical application of concepts related
More informationSchizophrenia and Related Psychotic Disorders
and Related Psychotic Disorders Anand K. Pandurangi, MD Professor & Chair, Div. of Inpatient Psychiatry Director, Program VCU Medical Center 1 Kraeplin 1896 Dementia Praecox. Single, Homogenous Disorder
More informationSynapses and Neurotransmitters.
Synapses and Neurotransmitters Loai.physiology@yahoo.com Communication Between Neurons Synapse: A specialized site of contact, and transmission of information between a neuron and an effector cell Anterior
More informationH1-Histamine Receptor Affinity Predicts Short-Term Weight Gain for Typical and Atypical Antipsychotic Drugs
(2003) 28, 519 526 & 2003 Nature Publishing Group All rights reserved 0893-133X/03 $25.00 www.neuropsychopharmacology.org H1-Histamine Receptor Affinity Predicts Short-Term Weight Gain for Typical and
More informationPSYCHOSIS IN PARKINSON'S DISEASE
PSYCHOSIS IN PARKINSON'S DISEASE Objectives Identify neurobiological substrates associated with Parkinson s disease psychosis Describe the differences between older antipsychotics and novel therapies for
More informationThe Impact of Mental Illness on Sexual Dysfunction
Balon R (ed): Sexual Dysfunction. The Brain-Body Connection. Adv Psychosom Med. Basel, Karger, 2008, vol 29, pp 89 106 The Impact of Mental Illness on Sexual Dysfunction Zvi Zemishlany Abraham Weizman
More informationSchizophrenia FAHAD ALOSAIMI
Schizophrenia FAHAD ALOSAIMI MBBS, SSC - PSYCH C ONSULTATION LIAISON PSYCHIATRIST K ING SAUD UNIVERSITY Schizophrenia - It is not a single disease but a group of disorders with heterogeneous etiologies.
More informationTreatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs
FEATURE REVIEW : a critical review of pharmacology and mechanisms of action of antipsychotic drugs S Miyamoto 1, GE Duncan 2, CE Marx 3 and JA Lieberman 2 (2005) 10, 79 104 & 2005 Nature Publishing Group
More informationTreat Schizophrenia Schizoaffective disorder Bipolar disorder Psychotic depression Off-label uses Insomnia Tics Delirium Stuttering
Robert M. Millay RN MSN Ed Professor, Napa Valley College Psychiatric Technician Programs Copyright 2015, 2011, 2007, 2003, 1999, 1995, 1991 by Mosby, an imprint of Elsevier Inc. Treat Schizophrenia Schizoaffective
More informationIs Lurasidone more safe and effective in the treatment ofschizoaffective disorder and schizophrenia than other commonanti-psychotic medications?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2015 Is Lurasidone more safe and effective
More informationSchizoaffective Disorder
Schizoaffective Disorder combination of schizophrenia symptoms (hallucinations or delusions) and mood disorder symptoms (such as mania or depression.) Controversial Requires presence of delusions for 2
More informationRole of Clozapine in Treatment-Resistant Schizophrenia
Disease Management and Treatment Strategies Elkis H, Meltzer HY (eds): Therapy-Resistant Schizophrenia. Adv Biol Psychiatry. Basel, Karger, 2010, vol 26, pp 114 128 Role of Clozapine in Treatment-Resistant
More informationAntipsychotic Use in the Elderly
Antipsychotic Use in the Elderly Presented by: Fatima M. Ali, PharmD, RPh, BCPS Clinical Consultant Pharmacist MediSystem Pharmacy, Kingston Originally Prepared by: Nicole Tisi BScPhm, RPh ACPR Disclosure
More informationAdvanced Neurotransmitters & Neuroglia
Advanced Neurotransmitters & Neuroglia Otsuka Pharmaceutical Development & Commercialization, Inc. 2017 Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville, MD Lundbeck, LLC. February
More informationDRUG TREATMENT OF PARKINSON S DISEASE. Mr. D.Raju, M.pharm, Lecturer
DRUG TREATMENT OF PARKINSON S DISEASE Mr. D.Raju, M.pharm, Lecturer PARKINSON S DISEASE (parkinsonism) is a neurodegenerative disorder which affects t h e b a s a l g a n g l i a - and is associated with
More informationThe impact of pharmacogenetics on the development and use of antipsychotic drugs
The impact of pharmacogenetics on the development and use of antipsychotic drugs Gavin P. Reynolds Division of Psychiatry and Neuroscience, Queen s University Belfast, Whitla Medical Building, 97 Lisburn
More informationChapter 4. Psychopharmacology. Copyright Allyn & Bacon 2004
Chapter 4 Psychopharmacology This multimedia product and its contents are protected under copyright law. The following are prohibited by law: any public performance or display, including transmission of
More informationIn February 2013, the FDA approved a
Long-acting injectable aripiprazole for adult schizophrenia Jana Lincoln, MD Depot formulation and once-monthly dosing might improve adherence in patients with schizophrenia 46 May 2013 In February 2013,
More informationDrugs used in schizophrenia قادة فریق علم الا دویة : الشكر موصول لا عضاء الفریق المتمیزین :
MCQs SAQs Summar y Drugs used in schizophrenia قادة فریق علم الا دویة : لین التمیمي & عبدالرحمن ذكري الشكر موصول لا عضاء الفریق المتمیزین : روان سعد القحطاني فؤاد بھجت عبدالرحمن العریفي حاتم النداح pharma436@outlook.com
More informationAPRIL 2008 DELHI PSYCHIATRY JOURNAL Vol. 11 No.1. Harish Arora, Rajdeep Kaur Department of Psychiatry, G.G.S. Medical College, Faridkot, Punjab
APRIL 2008 DELHI PSYCHIATRY JOURNAL Vol. 11 No.1 Original Article An Open Label Study on Amisulpride in Augmentation with Atypical Antipsychotics in Treatment Resistant Patients of Schizophrenia and Schizoaffective
More informationOlanzapine: Preclinical and Clinical Profiles of a Novel Antipsychotic Agent
CNS Drug Reviews Vol. 6, No. 4, pp. 303 363 2000 Neva Press, Branford, Connecticut Olanzapine: Preclinical and Clinical Profiles of a Novel Antipsychotic Agent Gary D. Tollefson and Cindy C. Taylor Lilly
More informationThe Cerebral Cortex and Higher Intellectual Functions
The Cerebral Cortex and Higher Intellectual Functions Lobes in a lateral view of left hemisphere Atlas Fig.2-11 The Insula The Hidden Lobe Atlas Fig. 2-11 Atlas Fig. 2-39 Lobes in a lateral view of left
More informationIn August 2009, the FDA approved asenapine
For mass reproduction, content licensing and permissions contact Dowden Health Media. p Asenapine for schizophrenia and bipolar I disorder Jana Lincoln, MD, and Sheldon Preskorn, MD In August 2009, the
More informationProviding an overview of antipsychotic drugs: is schizophrenia a psychiatric challenge?
Providing an overview of antipsychotic drugs: is schizophrenia a psychiatric challenge? Abstract Natalie Schellack, BCur, BPharm, PhD(Pharmacy), Senior Lecturer Moliehi Matlala, BPharm, MSc(Med) Pharmacy,
More informationThe study of drugs. Pharmacology
The study of drugs Pharmacology Psychopharmacology The study of psychoactive drugs Psychoactive drugs Drugs that influence psychological processes mood emotion perception cognition behavior Psychoactive
More informationChapter 3. Biological Processes
Biological Processes Psychology, Fifth Edition, James S. Nairne What s It For? Biological Solutions Communicating internally Initiating and coordinating behavior Regulating growth and other internal functions
More informationEARLY ONSET SCHIZOPHRENIA
Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences EARLY ONSET SCHIZOPHRENIA JON MCCLELLAN CHILD STUDY AND TREATMENT CENTER GENERAL DISCLOSURES The University of Washington
More informationUse of Antipsychotics in General Practice
Date : November, 01, 2009 Publication : Medical Chronicle Page Number: 75-76 Use of Antipsychotics in General Practice Page 1 / 5 Size=33SCKS$&imn OftraUftbonl 1999KSeddEserpp119999 Date : November, 01,
More informationBiomarkers in Schizophrenia
Biomarkers in Schizophrenia David A. Lewis, MD Translational Neuroscience Program Department of Psychiatry NIMH Conte Center for the Neuroscience of Mental Disorders University of Pittsburgh Disease Process
More informationChapter 17. Psychoses. Classifications of Psychoses. Schizophrenia. Factors Attributed to Development of Psychoses
Chapter 17 Psychoses Drugs for Psychoses Delusions Hallucinations Illusions Paranoia Upper Saddle River, New Jersey 07458 All rights reserved. Classifications of Psychoses Acute episode Chronic episode
More information